Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4D | Q6B0I6 | 16/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19627682 | 0.85 | KCNA3 (0.51) | KDM4DKCNA3KMT2AL3MBTL1 | |
| SCHEMBL19627679 | 0.85 | KCNA3 (0.51) | KDM4DKCNA3KMT2AL3MBTL1 | |
| SCHEMBL19613859 | 0.85 | EPHX2 (0.42) | KDM4DKMT2AL3MBTL1 | |
| SCHEMBL19613860 | 0.85 | EPHX2 (0.42) | KDM4DKMT2AL3MBTL1 | |
| SCHEMBL19613862 | 0.85 | EPHX2 (0.42) | KDM4DKMT2AL3MBTL1 | |
| SCHEMBL28839192 | 0.82 | KDM4D (0.47) | KDM4DKCNA3 | |
| SCHEMBL19613515 | 0.79 | MC4R (0.42) | — | |
| SCHEMBL19613518 | 0.79 | MC4R (0.42) | — | |
| SCHEMBL19613514 | 0.79 | MC4R (0.42) | — | |
| SCHEMBL18500471 | 0.76 | CTSK (0.56) | KDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-04-12 | — | — | US | disclosed |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-11-12 | — | — | US | disclosed |
| US-10815229-B1 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-10-27 | — | — | US | disclosed |
| US-10662184-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-05-26 | — | — | US | disclosed |
| US-20190194184-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2019-06-27 | — | — | US | disclosed |
| US-10246453-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2019-04-02 | — | — | US | disclosed |
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | US | disclosed |
| WO-2017201468-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | WO | disclosed |
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815229-B1 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | KDM4D 2444/4885DRD2 2365/4885KCNA3 41/4885 |
| US-10246453-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | KDM4D 2444/4885DRD2 2365/4885KCNA3 41/4885 |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | KDM4D 2444/4885DRD2 2365/4885KCNA3 41/4885 |
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | KDM4D 2444/4885DRD2 2365/4885KCNA3 41/4885 |
| US-10662184-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | KDM4D 2538/4885DRD2 2581/4885KCNA3 36/4885 |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | KDM4D 2444/4885DRD2 2365/4885KCNA3 41/4885 |
| US-20190194184-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | KDM4D 2538/4885DRD2 2581/4885KCNA3 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.